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Abstract
We herein review the state of knowledge regarding the in vitro and in vivo susceptibility of archaea to antimicrobial agents, including
some new molecules. Indeed, some archaea colonizing the human microbiota have been implicated in diseases such as periodontopathy.
Archaea are characterized by their broad-spectrum resistance to antimicrobial agents. In particular, their cell wall lacks peptidoglycan,
making them resistant to antimicrobial agents interfering with peptidoglycan biosynthesis. Archaea are, however, susceptible to the pro-
tein synthesis inhibitor fusidic acid and imidazole derivatives. Also, squalamine, an antimicrobial agent acting on the cell wall, proved
effective against human methanogenic archaea. In vitro susceptibility data could be used to design protocols for the decontamination of
complex microbiota and the selective isolation of archaea in anaerobic culture.
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Introduction
Archaea form a distinct kingdom of life, in addition to
eukaryotes, bacteria, and large DNA viruses [1,2]. Archaea
comprise three phylogenetically distinct groups: the
Crenarchaeota mainly consist of hyperthermophilic sul-
phur-dependent organisms, the Euryarchaeota contain metha-
nogens and extreme halophiles, and molecular evidence has
indicated the presence of the Korarchaeota in hyperthermo-
philic environments similar to those inhabited by the Cre-
narchaeota [3]. On the basis of their physiology, archaea can
be organized into methanogens, extreme halophiles, and
(hyper)thermophiles [4]. In addition to unifying features that
distinguish archaea from bacteria, archaea exhibit other
unique structural or biochemical characteristics related to
their particular habitats [4]. Antimicrobial susceptibility pat-
terns clearly distinguish archaea from the other organisms,
and antimicrobials active against most bacteria are ineffective
against archaea [5].
Methanogenic archaea (herein referred to as methano-
gens) are the sole organisms producing methane from
H2 + CO2 [6]. They are widely distributed in nature in terms
of their adaptation to different conditions of temperature,
pH, and salinity, but remain conﬁned to strictly anaerobic
environments. The observation that human breathing
released methane led to the isolation of the ﬁrst human
intestinal methanogen, Methanobrevibacter smithii [7]. Two
other species, Methanosphaera stadtmanae [8] and Methano-
massiliicocus luminyensis [9], were then isolated from the
human gut microbiota by the use of anaerobic culture
[10,11]. Methanobrevibacter oralis [12] was detected and iso-
lated from periodontitis specimens, with the same proce-
dure. Methanogens are perfectly adapted to their
environment, and play a role in the oral and intestinal micro-
biota [13]. M. smithii is the dominant methanogen in the
human gut, being detected with a high prevalence of 95.7%,
whereas Methanosphaera stadtmanae and Methanomassiliicocus
luminyensis are detected in 29.4% and 4% of individuals,
respectively [14].
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The gut is usually sterile at birth [15]. The development
and establishment of the intestinal microﬂora is a complex
process. It takes weeks or months to stabilize as a climax
microﬂora, a process that is inﬂuenced by diet. Methanogens
are detected until after weaning. It was generally reported
that this marked change in diet was concomitant with an
increase in the density and complexity of the microﬂora suf-
ﬁcient to produce the conditions that would allow further
colonization by methanogens [15]. Studies of the genetic
diversity of the human intestinal microbial community in rela-
tion to obesity, using culture-independent, molecular, phylo-
genetic and ecological statistical methods, showed that obese
individuals have distinctly different intestinal communities
than normal-weight individuals, conﬁrming an association
between methanogens and obesity [16,17]. Methanogens are
also detected in the human vagina [18]. It was shown that
diseased patients had a greater likelihood of being methano-
gen-positive, but no relationship was demonstrated between
patient condition and the presence of methanogens in the
vagina [18]. The potential role of archaea in digestive tract
disease, obesity and vaginal infection has not been ﬁrmly
established [17–19], whereas evidence has accumulated impli-
cating archaea in periodontitis [20,21].
Archaea are characterized by their broad-spectrum resis-
tance to antimicrobial agents [5]. Knowledge about their
behaviour towards antimicrobials is needed in the perspec-
tive of their potential pathogenic role. Also, antimicrobial
susceptibility patterns can be used to design protocols
for the decontamination of complex microbiota to select
archaea [22]. We herein review data regarding the antimi-
crobial susceptibility patterns of archaea, emphasizing the
methanogens found in humans.
Testing the Susceptibility of Archaea
In vitro susceptibility testing
In liquid medium, an archaeal inoculum of 10% (v/v) of a
stock solution is distributed in a series of tubes containing
the antimicrobial (macrodilution method). The inoculum is
determined by a 0.4 optical density at 580 nm corresponding
to (4.4212 ± 1.8411) cells/mL. After incubation, the MIC is
indicated by the ﬁrst tube exhibiting no visible growth [5]. In
solid medium, the antimicrobial is incorporated into agar
poured into Petri dishes. The archaeal inocula are then
spread over the surface of the agar. After incubation, the
MIC is determined by the inhibition of growth on the med-
ium containing the lowest concentration of the antimicrobial
[23]. Agar dilution, performed with a range of concentrations
in a geometric progression, is the reference method [24–26].
The density of the archaeal inoculum is paramount, and must
be adjusted with a photometer. Inocula were transferred in
each Petri dish, resulting in a ﬁnal inoculum of 105 cells/mL
[24,27]. The reliability of tests is inﬂuenced by many parame-
ters that must be strictly controlled. The culture medium
that allows growth of archaea does not contain antimicrobial
inhibitors [28]. The concentration of calcium and magnesium
should be monitored, as concentrations above 10 mM may
inhibit the activity of certain antimicrobials acting on mem-
branes [29]. Likewise, the pH inﬂuences the activity of sev-
eral antimicrobials [28]. The temperature and delay of
incubation must be ﬁxed [30]. Using a susceptible organism
as a positive control is mandatory [5].
Antimicrobials Acting on the Cell Wall
Cell-wall synthesis inhibitors
Bacterial cell walls contain peptidoglycan, with N-acetylmu-
ramic acid being the molecular signature for the presence of
peptidoglycan [31]. Archaea are considerably more diverse in
the composition of the cell wall; they lack peptidoglycan in
any form, but instead, proteins, glycoproteins and polysac-
charides cover the outside of the cell membrane [32]. In any
case, the functions of the cell wall remain the same: contain-
ing the cytoplasm, shaping the organism, and adapting to and
interacting with the environment [33].
b-Lactams, glycopeptides, lipoglycopeptide and fosfomycin
are the principal families of antimicrobials acting on the bac-
terial cell wall or bacterial cell-wall synthesis (Fig. 1). The
b-lactams include many bactericidal molecules. Their com-
mon features are a b-lactam nucleus and a similar mode of
action by inhibiting the ﬁnal step of peptidoglycan synthesis
[34]. Glycopeptides are huge molecules that cannot pass
through the porins. Their spectrum of activity is limited to
Gram-positive bacteria. Glycopeptides inhibit the synthesis
of peptidoglycan in its ﬁnal phase. The three-dimensional
structure of these molecules covers the D-Ala-D-Ala of
the pentapeptide-disaccharide, ready to be incorporated in
the peptidoglycan, preventing the action of glycosyl transfer-
ases and transpeptidases, and blocking the elongation of
peptidoglycan [35]. Fosfomycin acts at the earliest stage of
peptidoglycan synthesis, and must enter the cell to be
active [36].
Fosfomycin and antimicrobials directed against peptido-
glycan biosynthesis have no growth-inhibitory effect against
archaea with MICs of >50–100 mg/L [5,37]. The activity of
these antimicrobials against M. smithii has been investigated
with the reference strain DSMZ 861 (http://www.dsmz.de).
The high level of resistance of this strain to b-lactams and
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glycopeptides was demonstrated by isolation procedures
[22]. The resistance pattern of the faecal isolates agrees with
the structural differences between bacteria and archaea [5],
and this resistance is a natural attribute of these microorgan-
isms [22]. Lack of peptidoglycan is the only documented
mechanism of resistance. Indeed, different mesophilic metha-
nogenic and extremely halophilic archaea containing pseu-
domurein or glycoprotein cell walls were tested for b-
lactamase activity, with the chromogenic b-lactam nitroceﬁn
as substrate. No b-lactamase activity was detected in any of
the archaeal organisms [38]. This supports the view that b-
lactamases are absent in archaea and are restricted to bacte-
ria. Resistance to peptidoglycan inhibitors could be exploited
for the selective isolation of archaea from complex microbi-
ota. b-Lactams, glycopeptides and lipoglycopeptide are fre-
quently used to isolate methanogens from human specimens
containing a mixed microbiota, with the use of selective
media to purify methanogen cultures [22].
Cell-wall-alterating antimicrobials
Polymyxin. Polymyxin B and polymyxin E (also known as colis-
tin) are the two antimicrobial polypeptides used in clinical
practice. They have a rapid bactericidal action by disrupting
the lipidic components of membranes, including the lipopoly-
saccharide and the phospholipids [39]. Antimicrobial suscep-
tibility testing to polymyxin E was performed on the
haloalkaliphilic archaeon Halalkalicoccus tibetensis [40]. This
strain was reported to be resistant to polymyxin E and
several other antimicrobials, including penicillin, ampicillin,
streptomycin, tetracycline, bacitracin, neomycin, and sul-
phafurazole, and to be susceptible to rifampicin and novobio-
cin, but no MIC was determined in these studies. The
halophilic archaeon Natronococcus amylolyticus was found to
be resistant to polymyxin B [41]. The susceptibility of
halophilic archaea to this family of antimicrobial agents
appears to be dependent on the strain tested, and may differ
between closely related species [41,42]. Human methanogens
were found to be susceptible to bacitracin, with MICs of
<4 mg/L and <25 mg/L for M. oralis [5]. Such concentrations
are achieved by topical utilization of bacitracin in oral formu-
lations [43], suggesting that oral bacitracin could be used for
the treatment of periodontitis where M. oralis has been
implicated as a co-pathogen [20,21,44]. Susceptibility of
human archaea to bacitracin has been exploited in the for-
mulation of a medium for the selective isolation of Streptococ-
cus mutans from human dental plaque [45].
Amphotericin B. In 2010, a study focused on halophilic archaea
colonizing the human intestinal mucosa demonstrated the
resistance of these microorganisms to this antifungal agent.
Amphotericin B was therefore used in association with peni-
cillin and erythromycin at 100 mg/L, to repress growth of
salt-tolerant bacteria and fungi, with the aim of cultivating
halophilic archaea from the human intestinal mucosa speci-
men [46]. No data were provided for the other archaeal
families, including methanogens.
Squalamine and its derivatives. Squalamine is a potent, broad-
spectrum antimicrobial molecule extracted from the livers of
dogﬁsh and other shark species [47]. It acts on Gram-nega-
tive bacteria by a mechanism similar to that of colistin,
requiring interactions with the negatively charged phosphate
groups of the bacterial outer membrane as the ﬁrst step in a
sequence of different events leading to the disruption of the
membrane; squalamine exhibits a depolarizing effect on
Gram-positive bacteria, resulting in rapid cell death [29].
FIG. 1. Mode of action of antimicrobial agents against archaea. , Anti-archaeal activity observed. , No anti-archaeal activity observed.
PAB, p-aminobenzoic acid.
CMI Khelaiﬁa and Drancourt Susceptibility of archaea 843
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 841–848
Squalamine is also effective against human methanogens,
with an MIC of 1 mg/L [5] (S. Khelaiﬁa and M. Drancourt,
unpublished data). Our electron microscopy observations
suggest that squalamine breaks the M. smithii cell wall, induc-
ing cytoplasm leakage and cell death by a mechanism similar
to that observed for Gram-negative bacteria (Fig. 2). Unpub-
lished data from our laboratory indicate that human metha-
nogens are susceptible to squalamine and some of its
derivatives, with MICs between 0.1 and 1 mg/L (S. Khelaiﬁa
and M. Drancourt, unpublished data).
Antimicrobials interfering with DNA
DNA replication inhibition
DNA replication and transcription are targets for antimicro-
bials, including quinolones and novobiocin [48] (Fig. 1). Qui-
nolones are synthetic antibacterial agents that were initially
active against Gram-negative bacilli [48]. Quinolones enter
cells by simple diffusion, and selectively inhibit DNA replica-
tion in bacteria and some archaea, acting at the level of su-
percoiling, which causes a reduction in the space occupied
by DNA [48]. DNA gyrase is a topoisomerase involved in
DNA supercoiling [49–51]. Quinolones form an irreversible
ternary complex with the DNA gyrase, preventing gyrase
activity and blocking replication.
Coumermycin, a quinolone derivative, was studied on sev-
eral archaea at concentrations up to 200 mg/L. The results
showed the susceptibility of halobacterial archaea to this
compound, which also inhibits the growth of Sulfolobus acido-
caldarius and members of the Methanobacteriales, Methanococ-
cales and Methanomicrobiales [51]. The coumermycin MIC
depended on the strain. Halophilic archaea were more
susceptible, with an MIC of 5 mg/L, whereas thermophilic
archaea exhibited an MIC of >200 mg/L [51]. Novobiocin is a
bacteriostatic antimicrobial that is mainly active on Gram-
positive bacteria by inhibiting DNA replication through
preventing ATP binding to the DNA gyrase b-subunit [52].
Novobiocin was used to demonstrate the action of antimicro-
bial agents on the anaerobic digestion process [53]. The inhib-
itory action of novobiocin speciﬁcally affects the different
populations involved in the ﬁnal stage of anaerobic digestion.
This hypothesis was conﬁrmed by the lack of utilization of
acetate and the partial degradation of propionate and butyrate
[53].
Ansamycins form a family of secondary metabolites that
show antimicrobial activity against many Gram-positive and
some Gram-negative bacteria [54]. Moreover, ansamycins
demonstrated antiviral activity towards bacteriophages and
poxviruses [55]. Ansamycins inhibit the chaperone-mediated
folding of Hsp90 substrates by blocking their ATP-dependent
dissociation from Hsp90 [56]. The proeukaryote Hsp90
homologue HtpG is present in most bacterial species, but
not in archaea [57].
Accordingly, the ansamycin rifampicin was shown to be
ineffective on human archaea, with an MIC of >100 mg/L
[5]. H. tibetensis [40] is a haloalkaliphilic archaeon previ-
ously reported to be resistant to resistant to polymyxin E
and several other antimicrobials, including penicillin, ampi-
cillin, streptomycin, tetracycline, bacitracin, neomycin, and
sulphafurazole. This strain was reported to be susceptible
(a)
(b)
(c)
FIG. 2. Electronmicrographs showing the morphological effects of
squalamine on the Methanobrevibacter smithii cell wall. (a) M. smithii
without squalamine. (b) M. smithii + 1 lg/mL squalamine. (c) M. smi-
thii after 12 h of incubation in a culture medium containing 1 lg/mL
squalamine.
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to rifampicin, but no MIC was determined in these
studies.
DNA-altering antimicrobials: imidazole and derivatives
The spectrum of activity of imidazoles is limited to organisms
whose metabolism is anaerobic or at least micro-aerophilic,
such as Helicobacter pylori and Gardnerella vaginalis [58,59].
Indeed, imidazoles are prodrugs requiring partial reduction
of the NO2 group by anaerobic organisms [60,61]. Reduced
imidazole derivatives are biologically active products that
bind to DNA regions rich in adenine and thymine and cause
oxidative cleavage of DNA stretches. Such DNA lesions are
followed by the death of archaea and bacteria [59,61]. Met-
ronidazole, an imidazole derivative, was initially shown to
inhibit unidentiﬁed faecal methanogens with MICs between
0.5 and 64 mg/L [22]. It also showed in vitro activity against
human methanogens, with an MIC of 1 mg/L [5]. It was,
indeed, observed that treatment of the digestive tract with
metronidazole in bone marrow transplant recipients elimi-
nated detectable methanogens in stools: patients receiving
metronidazole were negative for methanogen culture within
the ﬁrst week of therapy, and recolonization occurred within
several weeks [62]. Gut decontamination with metronidazole
suppressed or eliminated the methanogens, just as it did the
anaerobic bacteria [63].
Nitrofurans are synthetic molecules used for treating
intestinal tract infections (furazolidone and nifuroxazide) and
urinary tract infections (nitrofurantoin and hydroxymethyl-ni-
trofurantoin) [64]. These molecules preferentially inhibit the
synthesis of inducible enzymes by blocking the initiation of
translation. The action of nitrofuran has implications for the
regulation of gene expression in general [65]. Nitrofurans
target DNA after reduction of the NO2 group by aerobic
bacterial nitroreductase [66]. Reduced derivatives break and
induce mutations in DNA. Their effect is bacteriostatic or
bactericidal, depending on the dose [67]. The anti-archaeal
activity of nitrofurantoin was conﬁrmed against the halo-
philic, aerobic archaea Halobiforma haloterrestris and Halogeo-
metricum borinquense, without the determination of MICs
[68].
DNA synthesis inhibitors: sulphonamides and benzylpyrimi-
dines
Sulphonamides are synthetic molecules that are often com-
bined with diaminopyridines (benzylpyrimidines) to increase
their activity and to reduce the risk of resistance emer-
gence. Sulphonamides are derivatives of p-aminobenzene-
sulphonic acid; the presence of a free amine and free
sulphur radicals directly substituting benzene are essential
for the antibacterial activity [69]. Sulphonamides and diami-
nopyridines inhibit the synthesis of folic acid, a key cofactor
in the synthesis of purine and pyrimidine bases in prokary-
otes [70,71], whereas eukaryotes directly assimilate folic
acid from the diet. A detailed inhibition study of carbonic
anhydrases belonging to the b and c carbonic anhydrase
families from archaea with sulphonamides was presented for
the ﬁrst time in 2004 [72]. The two susceptibility carbonic
anhydrases from Methanosarcina thermophila showed very
different inhibitory properties than those from Methanobac-
terium thermoautotrophicum. The most potent inhibitors were
sulphamic acid and acetazolamide, with MICs in the range
63–96 nM [72].
Protein Synthesis Inhibitors
The susceptibility of archaea to protein synthesis inhibitors
has been determined by several groups [73,74] (Fig. 1). It has
been known for some time that even closely related archaeal
species are remarkably heterogeneous in their sensitivity to
ribosome-targeted antimicrobials [75]. Many of the classical
inhibitors of eubacterial 70S and eukaryotic 80S ribosomes
do not inhibit the growth of these organisms even at high
concentrations; inhibition is caused by only a few compounds
that affect eubacterial and eukaryotic cells [5]. However, it is
unclear whether this lack of susceptibility is caused by the
impermeability of these organisms to most antimicrobials or
by the lack of a ribosomal binding site [73]. The susceptibility
of hyperthermophilic archaeal ribosomes to the inhibitory
actions of all known classes of aminoglycoside antimicrobial
has been tested on the hyperthermophilic Aquifex pyrophilus.
A. pyrophilus ribosomes are susceptible to all tested aminogly-
cosides, including 2-deoxystreptamines, monosubstituted
2-deoxystreptamines, and streptidine [76]. The effect of
selected aminoglycoside antimicrobials on the translational
accuracy of poly(U) programmed ribosomes derived from
the thermophilic archaea Thermoptasma acidophilum, Sulfolo-
bus solfataricus, Thermococcus celer and Desulfurococcus mobilis
showed that the four species investigated are markedly
diverse in their response to the miscoding-inducing action of
aminoglycoside antimicrobials [77]. A study of the suscepti-
bility of human methanogens showed high in vitro resistance
to gentamicin and streptomycin, with MICs of >100 mg/L
[5].
Tetracyclines bind to the 30S subunit of the bacterial ribo-
some [78]. First-generation tetracyclines were obtained from
chemical derivatives, doxycycline and minocycline, which
have better bioavailability and increased tissue distribution,
and a longer half-life for once-daily application [79]. Pacta-
mycin was isolated from Streptomyces pactum as a potential
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new human antitumour drug, but is in fact a potent inhibitor
of translation in eukaryotes, bacteria, and archaea [78].
Testing of the susceptibility of human archaea showed that
all tested human methanogens were resistant to tetracycline
at concentrations >100 mg/L [5].
Fusidic acid inhibits polypeptide chain elongation by bind-
ing to the ribosome elongation factor-G–GDP complex,
thereby preventing its dissociation [80]. The interactions of
fusidic acid with archaeal elongation factors were assayed by
using poly(U) programmed cell-free systems under optimal
culture conditions for polyphenylalanine synthesis. The
effects of fusidic acid on the polyphenylalanine-synthesizing
capacities of cell-free systems derived from representative
members of the families Methanobacteriaceae, Methanomicrobi-
aceae, and Methanococcaceae, the reference eubacterial Esc-
herichia coli and the eukaryotic Saccharomyces cerevisiae were
investigated. The elongation factor-G equivalent factor (elon-
gation factor-2) of all of the methanogens surveyed was sys-
tematically inhibited by fusidic acid within the same range of
effective concentrations as that affecting the functionally
homologous factors of E. coli and S. cerevisiae, at an MIC of
0.5 mg/L [81], supporting the hypothesis that archaea are
susceptible to molecules that are also active against bacteria
and eukaryotes [5].
Macrolides are active against Gram-positive and some
Gram-negative bacteria [82] by inhibiting the elongation of
the peptide chain after binding to the 50S subunit of bacterial
ribosomes [82,83]. As b-lactams, macrolides are frequently
used in association with other antimicrobial mixtures for lab-
oratory decontamination to isolate methanogens from
human specimens [22].
As previously described, erythromycin, an antimicrobial of
the macrolide family, was used to cultivate halophilic archaea
from human faeces [46]. These microorganisms were resis-
tant to concentrations of approximately 100 mg/L [46].
Phenicols
Chloramphenicol, thiamphenicol and ﬂorphenicol bind pref-
erentially to the A site at the 50S subunit [84]. The mecha-
nism of action of chloramphenicol remains unclear, but these
agents probably inhibit peptide binding and block chain elon-
gation [85].
Archaea are generally less sensitive to phenicols; the
growth of Halobacterium halobium and Sulfolobus acidocaldarius
is inhibited at elevated concentrations of chloramphenicol, at
MICs of ‡100 mg/L [86]. The in vitro susceptibility of human
archaea to chloramphenicol is variable. M. smithii, M. oralis
and Methanomassiliicocus luminyensis are resistant, with an
MIC up to 25 mg/L, in contrast to Methanosphaera stadtm-
anae, which exhibits an MIC of 4 mg/L [5]. The M. smithii,
M. oralis and Methanomassiliicocus luminyensis genomes encode
a chloramphenicol O-acetyltransferase, an enzyme that inacti-
vates chloramphenicol, but the gene for this is absent in the
Methanosphaera stadtmanae genome [5].
Conclusions
This review of the data regarding the susceptibility of ar-
chaea to antimicrobial agents indicates that these organisms
are broadly resistant to the antibiotics routinely used for the
treatment of bacterial infections in humans (Table 1). How-
ever, archaea are members of microbial communities, and
rely on bacterial metabolism for their own survival and mul-
tiplication. Therefore, the elimination of bacteria, including
anaerobes, in these communities could result in the indirect,
unexpected elimination of antibiotic-resistant archaea. If the
role of archaea in human infection is further documented
[19], then anti-archaeal compounds in addition to metronida-
zole and fusidic acid will be useful. Also, further studies
should aim to test the effectiveness of oral compounds such
as bacitracin against archaea implicated in periodontitis
[20,21].
Transparency Declaration
The authors have no conﬂict of interest regarding this paper.
TABLE 1. Classiﬁcation of antimicrobial agents according to their mode of action
Cell-wall synthesis inhibitors DNA-interfering antimicrobials Protein synthesis inhibitors Cell-wall-alterating antimicrobials
()) b-Lactams ()) Ansamycins ()) Tetracyclines ()) Polymyxins
()) Glycopeptide and lipoglycopeptide (+) Quinolones ()) Macrolides ()) Amphotericin B
()) Fosfomycin (+) Novobiocin ()) Lincosamides (+) Squalamine
(+) Imidazole ()) Erythromycin
(+) Nitrofurans ()) Phenicols
(+) Sulphonamides (+) Aminoglycosides
(+) Benzylpyrimidines (+) Fusidic acid
()), no anti-archeal activity observed; (+), anti-archeal activity observed.
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